A deficiency of microsomal triglyceride transfer protein reduces apolipoprotein B secretion

G K Leung1, M M Véniant, S K Kim

  • 1Gladstone Institute of Cardiovascular Disease, University of California, San Francisco, California 94141-9100, USA.

Insights

Reduced microsomal triglyceride transfer protein (MTP) levels impact apolipoprotein B (apoB) secretion by concentration, not MTP:apoB ratio. This finding is crucial for understanding lipoprotein metabolism and related diseases.

Area of Science:

  • Lipid Metabolism
  • Molecular Biology
  • Genetics

Background:

  • Microsomal triglyceride transfer protein (MTP) facilitates lipid transfer to apolipoprotein B (apoB) in the endoplasmic reticulum.
  • Previous studies suggested heterozygous MTP deficiency reduces apoB secretion, potentially due to an altered MTP:apoB ratio.

Purpose of the Study:

  • To investigate whether reduced apoB secretion in heterozygous MTP deficiency is caused by a lower MTP:apoB ratio.
  • To determine the critical determinant of lipoprotein secretion: MTP concentration or the MTP:apoB ratio.

Main Methods:

  • Examined apoB metabolism in heterozygous MTP knockout mice with normal, half-normal, and overexpressed apoB synthesis.
  • Assessed apoB secretion from primary hepatocytes under varying MTP and apoB levels.

Main Results:

  • Half-normal MTP levels consistently reduced plasma apoB100 levels by 25-35% across all apoB synthesis levels.
  • Hepatic apoB secretion was comparably reduced in primary hepatocytes regardless of apoB synthesis rate.
  • Heterozygous apoB deficiency resulted in greater plasma apoB100 reduction and hepatic triglyceride accumulation than heterozygous MTP deficiency.

Conclusions:

  • The concentration of MTP in the endoplasmic reticulum, not the MTP:apoB ratio, is the critical factor for lipoprotein secretion.
  • MTP levels play a more significant role in regulating apoB levels than previously thought, independent of apoB synthesis rates.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipid Absorption01:24

Lipid Absorption

Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Lipid Catabolism01:25

Lipid Catabolism

Triglycerides serve as crucial long-term energy storage molecules in microorganisms, providing a dense source of metabolic energy. Their breakdown is mediated by lipases, which hydrolyze triglycerides into glycerol and free fatty acids. Each of these components follows distinct metabolic pathways, ultimately contributing to ATP synthesis and cellular energy homeostasis.Glycerol MetabolismGlycerol, released from triglyceride hydrolysis, is phosphorylated by glycerol kinase to form...